127 related articles for article (PubMed ID: 20093557)
1. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.
Timms JF; Cramer R; Camuzeaux S; Tiss A; Smith C; Burford B; Nouretdinov I; Devetyarov D; Gentry-Maharaj A; Ford J; Luo Z; Gammerman A; Menon U; Jacobs I
Clin Chem; 2010 Feb; 56(2):262-71. PubMed ID: 20093557
[TBL] [Abstract][Full Text] [Related]
2. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
[TBL] [Abstract][Full Text] [Related]
3. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
[TBL] [Abstract][Full Text] [Related]
4. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
[TBL] [Abstract][Full Text] [Related]
5. [Identification of serum peptide biomarker for ovarian cancer diagnosis by Clin-TOF-II-MS combined with magnetic beads technology].
Xiu L; Li N; Wang WP; Chen F; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Cui W; Wu LY
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1188-1195. PubMed ID: 34794222
[No Abstract] [Full Text] [Related]
6. Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer.
Lee JH; Kim YH; Kim KH; Cho JY; Woo SM; Yoo BC; Kim SC
Cancer Res Treat; 2018 Jul; 50(3):883-893. PubMed ID: 28934848
[TBL] [Abstract][Full Text] [Related]
7. Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.
Wu S; Xu K; Chen G; Zhang J; Liu Z; Xie X
Int J Clin Oncol; 2012 Apr; 17(2):89-95. PubMed ID: 21638024
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling.
Sandanayake NS; Camuzeaux S; Sinclair J; Blyuss O; Andreola F; Chapman MH; Webster GJ; Smith RC; Timms JF; Pereira SP
BMC Clin Pathol; 2014 Feb; 14(1):7. PubMed ID: 24495412
[TBL] [Abstract][Full Text] [Related]
9. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC
Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935
[TBL] [Abstract][Full Text] [Related]
10. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples.
Lopez MF; Mikulskis A; Kuzdzal S; Golenko E; Petricoin EF; Liotta LA; Patton WF; Whiteley GR; Rosenblatt K; Gurnani P; Nandi A; Neill S; Cullen S; O'Gorman M; Sarracino D; Lynch C; Johnson A; Mckenzie W; Fishman D
Clin Chem; 2007 Jun; 53(6):1067-74. PubMed ID: 17463175
[TBL] [Abstract][Full Text] [Related]
11. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.
Freed GL; Cazares LH; Fichandler CE; Fuller TW; Sawyer CA; Stack BC; Schraff S; Semmes OJ; Wadsworth JT; Drake RR
Laryngoscope; 2008 Jan; 118(1):61-8. PubMed ID: 18043497
[TBL] [Abstract][Full Text] [Related]
12. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
[TBL] [Abstract][Full Text] [Related]
13. Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor.
Callesen AK; Madsen JS; Iachina M; Vach W; Kruse TA; Jensen ON; Mogensen O
Cancer Biomark; 2010; 6(2):73-82. PubMed ID: 20571233
[TBL] [Abstract][Full Text] [Related]
14. Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.
Timms JF; Menon U; Devetyarov D; Tiss A; Camuzeaux S; McCurrie K; Nouretdinov I; Burford B; Smith C; Gentry-Maharaj A; Hallett R; Ford J; Luo Z; Vovk V; Gammerman A; Cramer R; Jacobs I
Cancer Genomics Proteomics; 2011; 8(6):289-305. PubMed ID: 22086897
[TBL] [Abstract][Full Text] [Related]
15. Differential exoprotease activities confer tumor-specific serum peptidome patterns.
Villanueva J; Shaffer DR; Philip J; Chaparro CA; Erdjument-Bromage H; Olshen AB; Fleisher M; Lilja H; Brogi E; Boyd J; Sanchez-Carbayo M; Holland EC; Cordon-Cardo C; Scher HI; Tempst P
J Clin Invest; 2006 Jan; 116(1):271-84. PubMed ID: 16395409
[TBL] [Abstract][Full Text] [Related]
16. Identification of candidate biomarker mass (m/z) ranges in serous ovarian adenocarcinoma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Periyasamy A; Gopisetty G; Veluswami S; Joyimallaya Subramanium M; Thangarajan R
Biomarkers; 2015; 20(5):292-8. PubMed ID: 26329525
[TBL] [Abstract][Full Text] [Related]
17. Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures.
Velstra B; van der Burgt YE; Mertens BJ; Mesker WE; Deelder AM; Tollenaar RA
J Cancer Res Clin Oncol; 2012 Dec; 138(12):1983-92. PubMed ID: 22763645
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
[TBL] [Abstract][Full Text] [Related]
19. Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques.
Velstra B; Vonk MA; Bonsing BA; Mertens BJ; Nicolardi S; Huijbers A; Vasen H; Deelder AM; Mesker WE; van der Burgt YE; Tollenaar RA
J Cancer Res Clin Oncol; 2015 Mar; 141(3):531-41. PubMed ID: 25240825
[TBL] [Abstract][Full Text] [Related]
20. [Study for drug-resistance of epithelial ovarian cancer by serum protein profiling].
Zhang WY; Zhu LR; Zheng YH; Zhou L; Zhang JZ; Wu JH; Liao QP
Zhonghua Yi Xue Za Zhi; 2009 May; 89(19):1326-9. PubMed ID: 19615186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
